A-to-I RNA editing in hematologic immunity and malignancy

Area of Science:

• Biochemistry
• Immunology
• Hematology

Background:

• RNA editing, specifically adenosine-to-inosine (A-to-I) modification, is a critical post-transcriptional process.
• Adenosine deaminase acting on RNA 1 (ADAR1) is a key enzyme in A-to-I RNA editing.
• A-to-I RNA editing influences various cellular processes, including immune cell function and hematopoiesis.

Purpose of the Study:

• To review the multifaceted roles of A-to-I RNA editing in leukocytes.
• To emphasize the regulation of immune cell development and maturation by A-to-I RNA editing.
• To explore the contribution of dysregulated A-to-I RNA editing to malignant hematopoiesis.

Main Methods:

• Literature review focusing on A-to-I RNA editing in blood cells.
• Analysis of ADAR1's role in immune cell activity and hematologic malignancies.
• Examination of A-to-I RNA editing's impact on the efficacy of immune checkpoint inhibitors (ICIs).

Main Results:

• A-to-I RNA editing significantly impacts immune cell activity and development.
• Dysregulation of A-to-I RNA editing is implicated in the pathogenesis of hematologic malignancies.
• A-to-I RNA editing in immune cells is a determinant of response to therapies like ICIs.

Conclusions:

• A-to-I RNA editing is integral to normal leukocyte function and immune responses.
• Aberrant A-to-I RNA editing contributes to the development and progression of blood cancers.
• Targeting A-to-I RNA editing in immune cells holds promise for enhancing cancer immunotherapy efficacy.